Clinical trial
Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice
NCT07230691 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 3, 2025
- Completion date
- December 17, 2030
- Enrollment
- 380 (estimated)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.